Oramed Pharmaceuticals ORMP
NASDAQ ORMP
$4.49 +0.01 (+0.22%)
At close: Oct 2, 2026 · 4:00 PM EDT

Oramed Pharmaceuticals (ORMP) Asset Writedowns and Impairment (2012)

Updated

Oramed Pharmaceuticals' Asset Writedowns and Impairment was $141,143 in Q4 2012.

Analysis

Oramed Pharmaceuticals (ORMP) Asset Writedowns and Impairment (2012) Analysis & Trends

For FY2012, Asset Writedowns and Impairment at Oramed Pharmaceuticals came in at $184,254, down 6.7% from FY2011.

  • In earlier years, Asset Writedowns and Impairment was $197,412 in FY2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Oramed Pharmaceuticals 185.50 Mn 185.50 Mn -
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2012 141,143.00
Feb 29, 2012 43,111.00
API Access

Oramed Pharmaceuticals Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=ORMP&period=max&api_key=YOUR_API_KEY